5-氯-2-甲基-3-吡啶羧酸甲酯 | 350597-49-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯-2-甲基-3-吡啶羧酸甲酯
• 中文别名: 5-氯-2-甲基烟酸甲酯
• 英文名称: 2-methyl-5-chloro methylnicotinate
• 英文别名: methyl 5-chloro-2-methylnicotinate；methyl 5-chloro-2-methylpyridine-3-carboxylate；5-chloro-2-methyl-nicotinic acid methyl ester；5-chloro-2-methylnicotinic acid methyl ester
• CAS: 350597-49-8
• 化学式: C₈H₈ClNO₂
• mdl: MFCD09908061
• 分子量: 185.61
• InChiKey: KYEIGXOFICMHDP-UHFFFAOYSA-N

物化性质

• 熔点：
  45-47℃
• 沸点：
  233.5±35.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-chloro-2-methylnicotinate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-chloro-2-methylnicotinate
CAS number: 350597-49-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8ClNO2
Molecular weight: 185.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-2-甲基-3-吡啶羧酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 PPA 、 potassium tert-butylate 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 30.58h， 生成 3-chloro-7-[(2,4-dimethoxybenzyl)amino]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one
  参考文献：
  名称：

  Tyrosine kinase inhibitors

  摘要：

  本发明涉及5H-苯并[4,5]环庚[1,2-b]吡啶化合物，用于治疗细胞增殖性疾病，治疗与MET活性相关的疾病，以及抑制受体酪氨酸激酶MET。该发明还涉及包含这些化合物的组合物，以及利用它们治疗哺乳动物癌症的方法。

  公开号：

  US20060293358A1
• 作为产物：
  描述：

  (4Z)-methyl 2-acetyl-4-chloro-5-(dimethylamino)penta-2,4-dienoate 在 ammonium acetate 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 以95%的产率得到5-氯-2-甲基-3-吡啶羧酸甲酯
  参考文献：
  名称：

  A General Preparation of Pyridines and Pyridones via the Annulation of Ketones and Esters

  摘要：

  A general preparation of pyridines 4a-f from stabilized ketones 3a-c and aryl ketones 3d-f is described. The annulation of stabilized esters 3g,h gives access to the corresponding 2-pyridones 4g,h. The annulation reactions proceed in fair to excellent yields (46-87%) with vinamidinium hexafluorophosphate salts 2a-d containing electron-withdrawing groups at the beta -positisn. The mechanism of the reaction was investigated by NMR and proceeds through the formation of a dienaminone intermediate.

  DOI：

  10.1021/jo0155198

文献信息

• [EN] (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING<br/>[FR] DÉRIVÉS DE (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE ET COMPOSÉS ASSOCIÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA BÊTA-SÉCRÉTASE POUR LE TRAITEMENT
  申请人：COMENTIS INC

  公开号：WO2009042694A1

  公开（公告）日：2009-04-02

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

  本发明提供了新颖的β-分泌酶抑制剂及其使用方法，包括用于治疗阿尔茨海默病的方法。
• Tyrosine kinase inhibitors
  申请人：Avalle Paolo

  公开号：US20090182002A1

  公开（公告）日：2009-07-16

  This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl- 1 H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide, an inhibitor of tyrosine kinases, in particular the receptor tyrosine kinase MET, that are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. in particular, the invention relates to the sodium salt of N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide.

  这项发明涉及化合物N-[(2R)-1,4-二氧杂环戊烷-2-基甲基]-N-甲基-N′-[3-(1-甲基-1H-吡唑-4-基)-5-氧代-5H-苯并[4,5]环庚[1,2-b]吡啶-7-基]磺酰胺的盐形式，该化合物是一种酪氨酸激酶抑制剂，特别是受体酪氨酸激酶MET的抑制剂，对于治疗细胞增殖性疾病，例如癌症、增生、再狭窄、心肌肥大、免疫紊乱和炎症等疾病具有用处。特别是，该发明涉及N-[(2R)-1,4-二氧杂环戊烷-2-基甲基]-N-甲基-N′-[3-(1-甲基-1H-吡唑-4-基)-5-氧代-5H-苯并[4,5]环庚[1,2-b]吡啶-7-基]磺酰胺的钠盐。
• [EN] 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINE NMDA/NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINES DE NMDA/NR2B
  申请人：MERCK & CO INC

  公开号：WO2003084931A1

  公开（公告）日：2003-10-16

  Benzo [4,5]cyclohepta[1,2-b]pyridines represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  Benzo[4,5]环庚[1,2-b]吡啶代表的化学式（I）：或其药学上可接受的盐，作为NMDA NR2B拮抗剂，对缓解疼痛有效。
• [EN] HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE L'ACIDE HYDROXAMIQUE EN TANT QU'AGENTS CONTRE DES BACTÉRIES À GRAM NÉGATIF
  申请人：ASTRAZENECA AB

  公开号：WO2010100475A1

  公开（公告）日：2010-09-10

  The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.

  该发明涉及化学式(IB)的化合物或其盐。在某些实施例中，该发明涉及UDP-3-0-(R-S-羟基肉豆蔻酰)-N-乙酰葡萄糖胺脱乙酰酶(LpxC)的抑制剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物及其在预防和/或治疗革兰氏阴性细菌感染中的用途。
• Modular Access to Chiral α-(Hetero)aryl Amines via Ni/Photoredox-Catalyzed Enantioselective Cross-Coupling
  作者：Xiaomin Shu、De Zhong、Yanmei Lin、Xiao Qin、Haohua Huo

  DOI：10.1021/jacs.2c02795

  日期：2022.5.18

  (hetero)aryl chlorides. These coupling reactions require no oxidants or organometallic reagents, feature feedstock starting materials, a broad substrate scope, and high enantioselectivities, and are applicable to late-stage diversification of medicinally relevant complex molecules. Mechanistic studies suggest that the nickel catalyst uncommonly plays multiple roles, accomplishing chlorine radical generation

  手性 α-芳基 N-杂环通常存在于天然产物、药剂和手性催化剂中，但通过不对称催化获得仍然具有挑战性。在此，我们报告了一种用于饱和氮杂环和无环N的直接对映选择性 α-芳基化的通用模块化方法-烷基苯甲酰胺通过镍/光氧化还原双重催化。该过程利用光消除氯自由基的氢原子转移能力将氮杂环转化为相应的 α-氨基烷基自由基，然后与普遍存在且廉价的（杂）芳基氯化物偶联。这些偶联反应不需要氧化剂或有机金属试剂，具有原料起始材料、底物范围广和对映选择性高的特点，适用于药物相关复杂分子的后期多样化。机理研究表明，镍催化剂很少发挥多重作用，完成氯自由基的产生、α-氨基自由基的捕获、交叉偶联和不对称诱导。